Home » Achaogen, FDA Agree on SPA for Phase III Antibiotic Drug Trial
Achaogen, FDA Agree on SPA for Phase III Antibiotic Drug Trial
September 30, 2013
Achaogen and the FDA have come to an agreement on a Special Protocol Assessment related to a Phase III trial for plazomicin in patients with gram-negative infections that are resistant to multiple antibiotics.
Drug Discovery & Development Magazine
Drug Discovery & Development Magazine
Upcoming Events
-
21Oct